miR ‐30c‐5p inhibits esophageal squamous cell carcinoma progression by repressing the PI3K / AKT signaling pathway
Thoracic Cancer · 2024
DOI: 10.1111/1759-7714.15427 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Haochun Shi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Cell Proliferation, Disease Progression, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the National Natural Science Foundation of China, Postdoctoral Research Foundation of China, Research Foundation of Shanghai Municipal Health Commission.
Abstract (Originalsprache)
Background
Esophageal squamous cell carcinoma (ESCC) is one of the most common malignant tumors, with high incidence and poor prognosis. Revealing mechanisms of ESCC progression and developing new therapeutic targets remains crucial. The aim of this study was to elucidate the molecular mechanism of miR‐30c‐5p in regulating the malignant progression of ESCC.
Methods
TCGA, GEO, and other datasets were used to analyze the differential expression of miR‐30c‐5p in ESCC and adjacent tissues, and its impact on prognosis. Then the effects of miR‐30c‐5p on the proliferation, migration, and invasion of TE‐1 and Eca9706 cells were investigated through proliferation experiments, transwell and wounding healing assays. The regulatory mechanism of miR‐30c‐5p on the PI3K/AKT signaling pathway and its interaction in cancer progression were investigated through Western blots, dual‐luciferase reporter assay, and rescue experiments. Results miR‐30c‐5p was significantly downregulated in ESCC tissue and represented a poor prognosis. miR‐30c‐5p mimic significantly inhibited the proliferation, migration, and invasion ability of ESCC, while miR‐30c‐5p inhibitor significantly promoted tumor cell progression. Through bioinformatic analysis and experimental results, miR‐30c‐5p interacted directly with PIK3CA mRNA and inhibited subsequent signaling pathway activation. PIK3CA activator could eliminate the inhibitory effects of miR‐30c‐5p mimic on the progression of ESCC, while PIK3CA inhibitors could rescue the promoting effect of miR‐30c‐5p inhibitor group cells.
Conclusions
In summary, we found that miR‐30c‐5p inhibited the proliferation, invasion and migration of ESCC by inhibiting PI3K/AKT signaling pathway for the first time, and this study is expected to provide a novel insight and potential therapeutic target for managing ESCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Thoracic Surgery and Urology, Shigatse People's Hospital, Shigatse, China.
ORCID-Profile: Haochun Shi
Förderung
- the National Natural Science Foundation of China
- Postdoctoral Research Foundation of China
- Research Foundation of Shanghai Municipal Health Commission
- Natural Science Foundation of Tibet Autonomos Region
Zitieren
APA
Shi, H., Pan, B., Liang, J., Cai, B., Wu, G., Bian, Y., Shan, G., Ren, S., Huang, Y., & Guo, W. (2024). miR ‐30c‐5p inhibits esophageal squamous cell carcinoma progression by repressing the PI3K / AKT signaling pathway. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15427
Vancouver
Shi H, Pan B, Liang J, Cai B, Wu G, Bian Y, et al. miR ‐30c‐5p inhibits esophageal squamous cell carcinoma progression by repressing the PI3K / AKT signaling pathway. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15427
BibTeX
@article{Shi2024,
author = {Shi, Haochun and Pan, Binyang and Liang, Jiaqi and Cai, Benjie and Wu, Gujie and Bian, Yunyi and Shan, Guangyao and Ren, Shencheng and Huang, Yiwei and Guo, Weigang},
title = {miR ‐30c‐5p inhibits esophageal squamous cell carcinoma progression by repressing the PI3K / AKT signaling pathway},
journal = {Thoracic Cancer},
year = {2024},
doi = {10.1111/1759-7714.15427}
}
EUVIMED